Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181116 · ClinicalTrials.gov registry record · Phase 4
Levetiracetam for Benign Rolandic Epilepsy
A Phase 4 study of Epilepsy, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00181116 is a Phase 4 study of Epilepsy that has completed, run by Johns Hopkins University. The registered enrollment target is 6 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00181116, a Phase 4 study of Epilepsy, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to test if the language problems commonly seen in children with benign rolandic epilepsy would improve by switching anticonvulsants to levetiracetam.
Conditions Studied
Interventions
- DRUG Levetiracetam
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181116
The ClinicalTrials.gov registry entry for NCT00181116 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Levetiracetam is the first listed.
NCT00181116 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00181116 about?
NCT00181116 is a clinical study titled "Levetiracetam for Benign Rolandic Epilepsy". This study is designed to test if the language problems commonly seen in children with benign rolandic epilepsy would improve by switching anticonvulsants to levetiracetam.
What is the current status of trial NCT00181116?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2005-03. Estimated completion is 2006-09.
What conditions does trial NCT00181116 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00181116?
The interventions under investigation include: Levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00181116?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00181116 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care
RECRUITING · Phase 4
-
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
RECRUITING · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
-
Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia
COMPLETED · Phase 4
-
Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
COMPLETED · Phase 4
-
Fycompa Titration Intervals and Effects on Retention Rate
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.